269 related articles for article (PubMed ID: 27378194)
21. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E; Sinnett-Smith J; Kisfalvi K
Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
[TBL] [Abstract][Full Text] [Related]
22. MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
Lee J; An S; Jung JH; Kim K; Kim JY; An IS; Bae S
Int J Oncol; 2019 May; 54(5):1833-1842. PubMed ID: 30816444
[TBL] [Abstract][Full Text] [Related]
23. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
24. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Harada K; Ferdous T; Harada T; Ueyama Y
Int J Oncol; 2016 Jul; 49(1):276-84. PubMed ID: 27210058
[TBL] [Abstract][Full Text] [Related]
25. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
26. [New perspectives for metformin in cancer therapy].
Loubière C; Dirat B; Tanti JF; Bost F
Ann Endocrinol (Paris); 2013 May; 74(2):130-6. PubMed ID: 23587351
[TBL] [Abstract][Full Text] [Related]
27. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
28. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
Kawashima I; Mitsumori T; Nozaki Y; Yamamoto T; Shobu-Sueki Y; Nakajima K; Kirito K
Exp Hematol; 2015 Jul; 43(7):524-33.e1. PubMed ID: 25846811
[TBL] [Abstract][Full Text] [Related]
29. Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Thent ZC; Zaidun NH; Azmi MF; Senin MI; Haslan H; Salehuddin R
Curr Drug Targets; 2017; 18(6):734-750. PubMed ID: 27919208
[TBL] [Abstract][Full Text] [Related]
30. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
Chomanicova N; Gazova A; Adamickova A; Valaskova S; Kyselovic J
Physiol Res; 2021 Aug; 70(4):501-508. PubMed ID: 34062070
[TBL] [Abstract][Full Text] [Related]
31. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
32. Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.
Barczyński B; Frąszczak K; Kotarski J
J Drug Target; 2022 Apr; 30(4):359-367. PubMed ID: 34753372
[TBL] [Abstract][Full Text] [Related]
33. Metformin and gynecologic cancers.
Stine JE; Bae-Jump V
Obstet Gynecol Surv; 2014 Aug; 69(8):477-89. PubMed ID: 25144611
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
35. Activation of AMPK α2 inhibits airway smooth muscle cells proliferation.
Liu L; Pan Y; Song Y; Su X; Ke R; Yang L; Gao L; Li M
Eur J Pharmacol; 2016 Nov; 791():235-243. PubMed ID: 27600020
[TBL] [Abstract][Full Text] [Related]
36. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.
Al-Wahab Z; Mert I; Tebbe C; Chhina J; Hijaz M; Morris RT; Ali-Fehmi R; Giri S; Munkarah AR; Rattan R
Oncotarget; 2015 May; 6(13):10908-23. PubMed ID: 25895126
[TBL] [Abstract][Full Text] [Related]
37. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
38. Metformin as an antitumor agent in cancer prevention and treatment.
Li D
J Diabetes; 2011 Dec; 3(4):320-7. PubMed ID: 21631893
[TBL] [Abstract][Full Text] [Related]
39. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
[TBL] [Abstract][Full Text] [Related]
40. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
